Compass Pathways Announces Fourth Quarter and Full-Year 2024 Financial Results and Business Highlights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 27 2025
0mins
Should l Buy CMPS?
Source: Newsfilter
Clinical Trial Updates: Compass Pathways is progressing with its Phase 3 trials for COMP360 psilocybin treatment in treatment-resistant depression (TRD), expecting top-line data from the COMP005 trial in Q2 2025 and 26-week data from the COMP006 trial in H2 2026.
Financial Performance: The company reported a net loss of $155.1 million for 2024, with cash reserves of $165.1 million as of December 31, 2024, and raised an additional $150 million in January 2025 to support ongoing clinical programs.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CMPS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CMPS
Wall Street analysts forecast CMPS stock price to rise
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 8.380
Low
8.00
Averages
18.43
High
40.00
Current: 8.380
Low
8.00
Averages
18.43
High
40.00
About CMPS
Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in treating mental health conditions focused on rapid and durable responses through the development of its investigational COMP360 psilocybin treatment. COMP360 is its psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CMPS Stock Surges 41% This Week, Poised for Record Gains
- FDA Priority Review: Compass Pathways' COMP360 has been granted the Commissioner's National Priority Voucher by the FDA, allowing for a dramatically shortened review period of 1-2 months for its treatment-resistant depression application, thereby accelerating the market entry of this innovative therapy and enhancing the company's competitive edge.
- Analyst Ratings Optimistic: According to Koyfin, 11 out of 12 analysts covering CMPS rate it 'Buy' or higher, indicating strong market confidence in COMP360, with a projected 141% upside potential, which is likely to attract further investor interest.
- Strong Stock Performance: CMPS stock has surged 45% this week, with an additional 5.5% increase on Friday, marking the best week in the company's history and reflecting positive market expectations for its drug development, potentially drawing more capital inflows.
- High Market Sentiment: On Stocktwits, retail investor sentiment around CMPS remains in the 'extremely bullish' territory with extremely high message volume, indicating a strong optimistic outlook among investors regarding the company's future developments, further fueling the stock's rise.
See More
Compass Secures FDA Priority Review Support for COMP360
- FDA Priority Review: Compass Pathways has received a rolling NDA submission and review request from the FDA based on positive data from two large Phase 3 clinical trials, marking a significant advancement in the treatment of treatment-resistant depression and potentially accelerating its product launch timeline.
- National Priority Voucher Program: COMP360 has been selected for the FDA's National Priority Voucher program, which allows for a shortened review time of 1-2 months, enhancing Compass's market competitiveness and providing patients with quicker access to innovative treatment options that are urgently needed.
- Clinical Trial Results: COMP360 has demonstrated significant clinical effects in over 1,000 patients with treatment-resistant depression, showing effects as quickly as one day after administration, with durability lasting at least six months for those achieving a clinically meaningful response, offering new hope for patients.
- Urgent Market Demand: With approximately 4 million patients in the U.S. affected by treatment-resistant depression, Compass's innovative treatment could not only improve quality of life for these individuals but also potentially become the first breakthrough therapy in this field, addressing the growing market demand.
See More
COMP360 Receives FDA Priority Review Voucher
- FDA Priority Review: COMPASS Pathways' COMP360 has received an FDA Commissioner's National Priority Voucher, allowing for a review period of one to two months post-NDA submission, significantly shortening the approval timeline and enhancing market competitiveness.
- Rolling Submission Approval: The FDA has granted COMPASS Pathways' request for a rolling submission, enabling the company to submit data incrementally during the NDA process, thereby accelerating communication with the FDA and optimizing the approval workflow.
- Clinical Trial Success: In February, COMP360 achieved its primary endpoint in a late-stage trial, demonstrating its efficacy in treating treatment-resistant depression, which lays a solid foundation for future market launch efforts.
- Positive Market Outlook: As a leader in the psychedelic market, COMPASS Pathways is expected to attract increased investor interest following the FDA's favorable feedback and successful clinical trials, likely driving the company's stock price upward.
See More
FDA Accelerates Development of Psychedelic Treatments for Mental Health
- Regulatory Push: The FDA has announced plans to accelerate the development of psychedelic treatments to address serious mental health issues, particularly post-traumatic stress disorder and treatment-resistant depression, indicating strong support for innovative therapies.
- Presidential Directive: Last week, President Trump signed an executive order directing health agencies to expedite research on psychedelic substances like psilocybin, MDMA, and ibogaine, aiming to swiftly tackle the national mental health crisis, especially for veterans.
- Market Reaction: Following the FDA's new policy, shares of Compass Pathways Plc. (CMPS), Helus Pharma Inc. (HELP), and Enveric Biosciences Inc. (ENVB) rose between 2% and 7% in Friday's opening trade, reflecting investor optimism about the psychedelic drug market's potential.
- Industry Outlook: This FDA initiative not only paves the way for clinical applications of psychedelics but may also encourage more companies to enter this emerging market, thereby driving innovation and growth among related firms.
See More
B. Riley Begins Coverage of Compass Pathways PLC with a Buy Rating and Sets Price Target at $17
Company Overview: Compass Pathways PLC, led by B. Riley, is initiating coverage with a focus on its market potential.
Investment Recommendation: The firm has issued a "Buy" rating for Compass Pathways, indicating confidence in its growth prospects.
Price Target: A price target of $17 has been set for Compass Pathways shares, suggesting expected appreciation.
Market Context: The coverage initiation reflects a strategic move to highlight the company's position within the industry.
See More
Trump Signs Executive Order on Psychedelic Therapy Review
- Accelerated Review Process: President Trump's executive order aims to shorten the timeline for clinical trials and regulatory reviews of psychedelic therapies, which will enhance acceptance among patients and providers, thereby increasing the investment value of the psychedelics sector.
- COMP360 Clinical Progress: Compass Pathways' COMP360 is in pivotal phase 3 development, demonstrating significant efficacy in treating treatment-resistant depression, with plans to submit a New Drug Application in Q4 2023, marking a critical milestone in its clinical advancement.
- Sufficient Funding Assurance: Compass Pathways reported $149.6 million in cash and cash equivalents at the end of 2025, with an annual cash burn of $120 million to $145 million, ensuring it can smoothly advance to the final development stage without the risk of running out of capital.
- Institutional Investor Confidence: Approximately 46% of Compass Pathways' shares are held by institutional investors and hedge funds, reflecting strong market confidence in its clinical data and regulatory progress, further enhancing its competitiveness in the psychedelics field.
See More
CMPS Stock Surges 41% This Week, Poised for Record Gains
- FDA Priority Review: Compass Pathways' COMP360 has been granted the Commissioner's National Priority Voucher by the FDA, allowing for a dramatically shortened review period of 1-2 months for its treatment-resistant depression application, thereby accelerating the market entry of this innovative therapy and enhancing the company's competitive edge.
- Analyst Ratings Optimistic: According to Koyfin, 11 out of 12 analysts covering CMPS rate it 'Buy' or higher, indicating strong market confidence in COMP360, with a projected 141% upside potential, which is likely to attract further investor interest.
- Strong Stock Performance: CMPS stock has surged 45% this week, with an additional 5.5% increase on Friday, marking the best week in the company's history and reflecting positive market expectations for its drug development, potentially drawing more capital inflows.
- High Market Sentiment: On Stocktwits, retail investor sentiment around CMPS remains in the 'extremely bullish' territory with extremely high message volume, indicating a strong optimistic outlook among investors regarding the company's future developments, further fueling the stock's rise.
See More
Compass Secures FDA Priority Review Support for COMP360
- FDA Priority Review: Compass Pathways has received a rolling NDA submission and review request from the FDA based on positive data from two large Phase 3 clinical trials, marking a significant advancement in the treatment of treatment-resistant depression and potentially accelerating its product launch timeline.
- National Priority Voucher Program: COMP360 has been selected for the FDA's National Priority Voucher program, which allows for a shortened review time of 1-2 months, enhancing Compass's market competitiveness and providing patients with quicker access to innovative treatment options that are urgently needed.
- Clinical Trial Results: COMP360 has demonstrated significant clinical effects in over 1,000 patients with treatment-resistant depression, showing effects as quickly as one day after administration, with durability lasting at least six months for those achieving a clinically meaningful response, offering new hope for patients.
- Urgent Market Demand: With approximately 4 million patients in the U.S. affected by treatment-resistant depression, Compass's innovative treatment could not only improve quality of life for these individuals but also potentially become the first breakthrough therapy in this field, addressing the growing market demand.
See More
COMP360 Receives FDA Priority Review Voucher
- FDA Priority Review: COMPASS Pathways' COMP360 has received an FDA Commissioner's National Priority Voucher, allowing for a review period of one to two months post-NDA submission, significantly shortening the approval timeline and enhancing market competitiveness.
- Rolling Submission Approval: The FDA has granted COMPASS Pathways' request for a rolling submission, enabling the company to submit data incrementally during the NDA process, thereby accelerating communication with the FDA and optimizing the approval workflow.
- Clinical Trial Success: In February, COMP360 achieved its primary endpoint in a late-stage trial, demonstrating its efficacy in treating treatment-resistant depression, which lays a solid foundation for future market launch efforts.
- Positive Market Outlook: As a leader in the psychedelic market, COMPASS Pathways is expected to attract increased investor interest following the FDA's favorable feedback and successful clinical trials, likely driving the company's stock price upward.
See More
FDA Accelerates Development of Psychedelic Treatments for Mental Health
- Regulatory Push: The FDA has announced plans to accelerate the development of psychedelic treatments to address serious mental health issues, particularly post-traumatic stress disorder and treatment-resistant depression, indicating strong support for innovative therapies.
- Presidential Directive: Last week, President Trump signed an executive order directing health agencies to expedite research on psychedelic substances like psilocybin, MDMA, and ibogaine, aiming to swiftly tackle the national mental health crisis, especially for veterans.
- Market Reaction: Following the FDA's new policy, shares of Compass Pathways Plc. (CMPS), Helus Pharma Inc. (HELP), and Enveric Biosciences Inc. (ENVB) rose between 2% and 7% in Friday's opening trade, reflecting investor optimism about the psychedelic drug market's potential.
- Industry Outlook: This FDA initiative not only paves the way for clinical applications of psychedelics but may also encourage more companies to enter this emerging market, thereby driving innovation and growth among related firms.
See More
B. Riley Begins Coverage of Compass Pathways PLC with a Buy Rating and Sets Price Target at $17
Company Overview: Compass Pathways PLC, led by B. Riley, is initiating coverage with a focus on its market potential.
Investment Recommendation: The firm has issued a "Buy" rating for Compass Pathways, indicating confidence in its growth prospects.
Price Target: A price target of $17 has been set for Compass Pathways shares, suggesting expected appreciation.
Market Context: The coverage initiation reflects a strategic move to highlight the company's position within the industry.
See More
Trump Signs Executive Order on Psychedelic Therapy Review
- Accelerated Review Process: President Trump's executive order aims to shorten the timeline for clinical trials and regulatory reviews of psychedelic therapies, which will enhance acceptance among patients and providers, thereby increasing the investment value of the psychedelics sector.
- COMP360 Clinical Progress: Compass Pathways' COMP360 is in pivotal phase 3 development, demonstrating significant efficacy in treating treatment-resistant depression, with plans to submit a New Drug Application in Q4 2023, marking a critical milestone in its clinical advancement.
- Sufficient Funding Assurance: Compass Pathways reported $149.6 million in cash and cash equivalents at the end of 2025, with an annual cash burn of $120 million to $145 million, ensuring it can smoothly advance to the final development stage without the risk of running out of capital.
- Institutional Investor Confidence: Approximately 46% of Compass Pathways' shares are held by institutional investors and hedge funds, reflecting strong market confidence in its clinical data and regulatory progress, further enhancing its competitiveness in the psychedelics field.
See More
